Since its inception in 2005, India Globalization Capital (NYSE: IGC) has transitioned from a mining company to a developer of cannabis-based therapies. The company is unique in that it uses cannabis-based extracts in combination with other medications to reduce side effects and increase bioavailability and absorption. “The company now has a pipeline of patent pending cannabinoid-based drugs targeting large market maladies, which includes therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy and eating disorders. Several of these therapeutic drugs are scheduled for pre-clinical trials this year. The company is transitioning fast from building research teams and developing a patent portfolio to marketable products.”
Read the full article
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Read More